Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (16987)	7/3/2004 11:07:30 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Circa 2003........Both BPI and the lipoxins are currently the subject of intensive biopharmaceutical development, >kinda makes you wonder sometimes their choice of words... >kinda makes you wonder who, where, and what......

To: Robert K. who wrote (16987)	7/3/2004 12:21:33 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Thinking out loud here.....bpi DOES allieviate endotoxin mediated TNF (think tnf for a second), ....wouldnt it be something if bpi allieviated NON-endotoxin mediated TNF... Think about it... >a SAFE tnf inhibitor? Is there a need for that or what. Thats most likely a very very longshot , but enbrel, raptiva & bpi etc all might provide a desired cocktail when used in combo. Example >raptiva/skin, bpi skin inflamation Or how about all that bpi-anca in arthritis used in conjuction with enbrel or even raptiva. Believe me raptiva aint gonna get dismissed in Ra or PSA. The much more likely outcome is a CLEANER retest with an NOW-approved med. skd always